StemCyte Differentiator
Global Presence
StemCyte Inc. USA was established in 1997. More than instead of greater than 20 years experience in cord blood banking.
Global footprint with operations in USA, Taiwan and India.
StemCyte India is a joint venture of StemCyte Inc.(USA), Apollo Hospitals and Cadila Pharmaceuticals.
The Apollo and Cadila partnership More than instead of greater than 20 instead of 68 years of experience in the health service industry.
Highest Quality & Standards
StemCyte is the highest accredited stem cell bank – FACT, AABB, ISO, NABL, WHO-GMP, FDA
USFDA approved collection bag, freezing bag, canisters, etc. are truly imported
FDA approved insulated kit box is fire resistant and tough
Our endeavor is to ensure that we meet the highest quality accredited standards by following 400 SOPs diligently
24/7 customer support at all stages – collection, testing, storage, retrieval and transplantation
‘Hybrid+’ Model
Public Bank – The UCB is donated to StemCyte for processing & storage for further use by unrelated patients
Private Bank – UCB is collected, processed & stored solely for the future medical needs of the child or the family
Advanced Therapeutics – Treatment of patients in need
Clinical Trials – Use of cord blood stem cells in indications like spinal cord injuries, stroke, etc.
Plasma Depletion Technique
One of the most important aspects in cord blood transplantation is the recovery of stem cells
StemCyte’s patented plasma depletion technology ensures upto 99.96% cell recovery
Patient transplanted with plasma depleted cord blood receive
- Higher cell dose
- Lower transplant related mortality
- Superior engraftment
- Overall survival
- Higher rate of Survival
StemCyte’s International Experts
Dr. Wise Young, (M.D, PhD)
Chief Medical Director“Extensive work on spinal cord injury”
Dr. Lawrence D. Petz, (M.D.)
Global Medical Director“Proven cord blood stem cell transplant for treatment of HIV”
Dr. Tang-Her Jaing
Associate Professor,
Division of Hematology, Oncology, Department of Pediatrics, Chang Gung Children’s Hospital, Taiwan“More than 120 transplants for Thalassemia”
Clinical Trials & Research by StemCyte’s Experts
StemCyte is actively involved in clinical trials and research studies, to further the science of saving lives using cord blood stem cells and cord tissue
Current clinical trials are as follows:
- Spinal cord injury
- Stroke
- HIV
- Cardiac repair
- Optic nerve
- Autism
- Cerebral Palsy
- Ischemia
Transplant Experience: Unmatched in the Industry
StemCyte : The most experienced cord blood bank
- Has participated in more than 2084 transplants across 315 transplant centers in 38 countries on 6 continents
- Facilitators of 47 transplants in India, within a span of 6 years??
“Click below link to get the complete details of transplants done by StemCyte India:”
StemCyte’s Unit is sufficient to treat Adult patients
5 million cells are required to treat 1 Kg body weight – reference PCGB
StemCyte’s Unit has Avg TNC count of 120 * 107
Stemcyte has treated a patient with 75 kg body with using 1 single Unit
StemCyte is the only company to treat RARE diseases
StemCyte has treated HLH : 22 patients worldwide and 2 in India
StemCyte India has treated 1 patient of CEP
StemCyte has also treated Hurler’s syndrome, Mucopolysaccharidosis (MPS) and Mylodisplastic Syndrome (MDS)
StemCyte has experience in overall treating 58 diseases
StemCyte Does a Chemical free processing
PD technology is does not use HES or any other chemical
USE of HES can increase mortality if used in cord blood
The European EMA made the decision that hydroxyethyl starch (HES) should no longer be used in patients with sepsis or burn injuries, or in critically ill patients (EMA, 2015) (15).
FDA warns to use HES for processing of cord blood (Reference FDA website)